Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Why?

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 17, 2024 8:25am

284 Views

Post# 35830739

RE:Why?

Right - it wasn't generated from inside the company - so - why would a title matter from outside the company?

Hint - we already knew it was a pre-merger company. I just hope that doesn't happen for a very long time. I have other plans for this one.

Whatever hype that title generates ... is only that, hype.

The proof is in P2 and in how well they execute. Determining pass/fail for OTENA. Nothing else matters. Eyes on the prize and on the 18th for some details. You're listent to how we get to that prize.

The science is the puzzle ... always been the puzzle. Can it be solved?

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario